Orforglipron (Foundayo)
Oral GLP-1 Receptor Agonist | FDA-Approved for Weight Reduction
On this page
What is Orforglipron (Foundayo)?
Orforglipron is a small-molecule medicine (not a peptide) that activates the same GLP-1 receptor pathway as injectable diabetes and weight-management drugs, but is taken as a once-daily pill. It's the first oral, non-peptide GLP-1 medicine to receive FDA approval, and it's one of the most heavily studied compounds in the current metabolic-research literature. Research-grade orforglipron sold here is intended for laboratory research use only — it is not the same product as, and is not a substitute for, an approved prescription medication.
Key terms:
Orforglipron (Foundayo) is a small molecule.
Orforglipron (brand name Foundayo) is an FDA-approved oral GLP-1 receptor agonist — it mimics a gut hormone affecting appetite and blood sugar. It is a small molecule, not a peptide, and the first small-molecule GLP-1 approved for weight management. The FDA approved it in April 2026 under its National Priority Voucher program. Foundayo can be taken once daily at any time, without food or water restrictions. In clinical trials, participants on the highest approved dose (17.2mg) reached up to 11.1% weight reduction (24.9 lbs) at 72 weeks. Trials also reported robust glycemic control, with HbA1c reductions of 1.3-1.6%. Chugai Pharmaceutical developed it; Eli Lilly markets it. Tablets come in 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, and 17.2mg.
Key research areas
- FDA-approved for weight reduction (up to 11.1% at 72 weeks)
- Robust diabetes control (HbA1c reduction 1.3-1.6%)
- Once-daily oral tablet taken any time of day
- No refrigeration or food/water restrictions required
- Reduced cardiovascular risk markers
- Available as low as $25/month with insurance
Researched dosing
This table reflects how researchers structure orforglipron study designs — the titration schedules used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Starting dose (first 30 days) | 0.8mg daily | Once daily, any time | Oral tablet |
| Second step (after 30 days) | 2.5mg daily | Once daily, any time | Oral tablet |
| Third step (after 60 days) | 5.5mg daily | Once daily, any time | Oral tablet |
| Fourth step (response-based) | 9mg daily | Once daily, any time | Oral tablet |
| Fifth step (response-based) | 14.5mg daily | Once daily, any time | Oral tablet |
| Highest approved dose | 17.2mg daily | Once daily, any time | Oral tablet |
Commonly cycled 72 weeks on, 0+ weeks off.
How it works
At the cell level, orforglipron research looks at how the molecule activates GLP-1 receptors to influence insulin release, digestion speed, and appetite signaling — similar targets to injectable GLP-1 peptides, but reached through a small-molecule structure instead of a peptide chain.
Small-molecule GLP-1 receptor agonist with biased signaling - preferentially activates G protein/cAMP pathways (enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, reducing appetite) while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life supporting once-daily dosing.
Pharmacokinetics
This chart plots how long a research dose of orforglipron stays active in the literature — its multi-day clearance curve is part of why the approved medication built on this compound is taken just once a day.
- Peak
- 8 hr
- Half-life
- 38.4 hrs
- Cleared
- ~194.4 hrs
Eli Lilly Phase 1 Studies
Research applications
This section lists the research areas — weight management and metabolic research chief among them — that scientists have studied for orforglipron in the clinical literature; research-grade orforglipron sold here is intended for laboratory study only, not human use.
Weight Reduction
FDA-approved based on ATTAIN-1 trial: 17.2mg dose achieved 11.1% weight reduction (24.9 lbs) at 72 weeks in non-diabetic adults with obesity. 9mg achieved 8.3% (18.9 lbs), 5.5mg achieved 7.4% (17.2 lbs). First oral small-molecule GLP-1 approved for weight management. ATTAIN-2 Phase 3 trial showed 9.6% weight reduction (21.2 lbs) with 17.2mg in patients with both obesity and diabetes. Significant improvements in waist circumference, systolic blood pressure (8-12 mmHg reductions), triglycerides (-20-30%), and non-HDL cholesterol across Phase 3 trials. Among 1,127 ATTAIN-1 participants with prediabetes at baseline, up to 91% achieved near-normal blood sugar levels vs 42% with placebo.
Diabetes
ACHIEVE-1 Phase 3 trial: All doses significantly reduced HbA1c by 1.3-1.6% from 8.0% baseline vs 0.4% placebo. 76.2% achieved HbA1c <7%, 66.0% achieved ≤6.5%. First oral GLP-1 with no food/water restrictions to complete Phase 3.
Cardiovascular
Significant improvements in waist circumference, systolic blood pressure (8-12 mmHg reductions), triglycerides (-20-30%), and non-HDL cholesterol across Phase 3 trials. Comprehensive metabolic syndrome reversal.
Dosage reference
- Doses used in research
- Published trials started at 0.8 mg daily, moved to 2.5 mg after 30 days and 5.5 mg after 60 days. Higher steps of 9, 14.5 and 17.2 mg were also studied.
- Frequency in studies
- Once daily, same time each day preferred
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Appetite reduction 1-3 days, glucose improvements 1-4 weeks, weight reduction 2-4 weeks, peak effects 16-36 weeks
- Storage
- Room temperature (15-30°C), no refrigeration required
- Cycle length
- Long-term continuous therapy (72+ weeks studied)
- Break between cycles
- Consult prescriber before discontinuation to manage potential rebound effects
Interactions
This list shows which other metabolic-research compounds scientists study alongside orforglipron, and flags pairings that call for extra caution or monitoring in a research setting.
Reconstitution & storage
Orforglipron is studied as an oral tablet rather than an injectable, so this section covers handling and storage notes instead of a mixing procedure.
- Orforglipron is an oral tablet that requires no reconstitution or special preparation
- Choose any convenient time of day (morning, afternoon, or evening)
- If a dose is missed, take it as soon as remembered on the same day
- If remembered on the next day, skip the missed dose and resume normal schedule
- Never double dose to make up for a missed tablet
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: 15-30°C, use within Until expiration date on packaging
Reconstituted: 2-6°C, use within N/A - oral tablet, no reconstitution required
Quality indicators
This section lists what a researcher checks — packaging integrity, tablet consistency, verified sourcing — to confirm an orforglipron sample matches its labeled specification before use in a study.
Intact tablet packaging with proper labeling - Tablets should be in sealed blister packs or bottles with clear dosage labeling, batch numbers, and expiration dates. Packaging should show no signs of tampering.
Uniform tablet appearance and consistency - Tablets should have consistent color, shape, and size without discoloration, chipping, or cracking. Small molecule tablets should appear professionally manufactured.
Proper storage conditions maintained - Stored at room temperature (15-30°C) in dry environment away from direct sunlight, moisture, and heat. No refrigeration required unlike peptide GLP-1 agonists.
Valid prescription and legitimate pharmacy source - Product obtained through a licensed pharmacy, LillyDirect, or authorized telehealth provider with valid prescription. Look for official Foundayo branding and Eli Lilly packaging.
Discolored, crumbling, or damaged tablets - Tablets showing signs of degradation, unusual colors (yellowing, browning), brittleness, or physical damage indicate improper storage or expired product.
Moisture exposure or humidity damage - Tablets that feel soft, sticky, or show signs of moisture absorption. Package should protect from humidity. Damaged packaging compromises tablet stability.
Unverified or non-pharmacy sources - Only obtain Foundayo through licensed pharmacies, LillyDirect, or authorized telehealth providers. Products from unregulated online sources may be counterfeit or improperly stored.
Suspiciously low pricing or unregulated sources - Foundayo is available from $25/month with insurance or $149/month self-pay at the lowest dose. Products offered far below these prices from unregulated sources may be counterfeit or contaminated.
What to expect
This timeline reflects what the clinical literature reports at each study stage — research context for comparing studies, not a personal-results promise.
Appetite reduction typically within 1-3 days of first dose. Mild to moderate nausea common (usually improves significantly). Diarrhea possible (19-26% of patients) - stay well hydrated.
Gradual weight reduction begins (0.5-2 lbs per week). Improved blood sugar control within 1-4 weeks for diabetic patients. GI side effects generally diminish after first month.
Reduced food cravings and enhanced satiety throughout the day. Energy levels normalize after initial adaptation period. Improved metabolic markers (blood pressure, lipids) become evident.
Continued progressive weight reduction without plateau. Peak weight reduction effects typically seen at 36-72 weeks. Sustained improvements in cardiovascular risk factors.
Long-term therapy well-tolerated in clinical trials. Participants show sustained benefits without plateau at 72 weeks. Ongoing diabetes prevention and metabolic health improvements.
Safety notes
This section summarizes orforglipron's regulatory status and handling notes — safety and contraindication data drawn from the clinical literature on the approved medication, provided here as reference context for laboratory researchers, not medical guidance.
- BOXED WARNING: May cause thyroid C-cell tumors including medullary thyroid carcinoma (MTC). Contraindicated in patients with personal/family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Do not use with other GLP-1 receptor agonist medicines
- Monitor for signs of acute pancreatitis - stop taking Foundayo immediately if suspected
- May cause dehydration leading to kidney problems - drink fluids to reduce risk
- May affect oral contraceptive efficacy - use alternative birth control for 30 days after starting and after each dose increase
- May require adjustment of insulin or sulfonylurea doses to prevent hypoglycemia
- Not safe during pregnancy or breastfeeding
- Gallbladder problems reported - monitor for upper abdominal pain, fever, jaundice
- FDA-approved April 2026 under the National Priority Voucher program for weight management
- Available by prescription only through licensed pharmacies or authorized telehealth providers
Regulatory status
- Approved by the FDA for at least one indication. That approval applies to regulated pharmaceutical products, not to research-grade material.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Highest approved dose (17.2mg) achieved 11.1% weight reduction (24.9 lbs) vs 2.1% placebo. 9mg achieved 8.3% (18.9 lbs), 5.5mg achieved 7.4% (17.2 lbs). Significant improvements in waist circumference, blood pressure, triglycerides, and non-HDL cholesterol.
Highest approved dose (17.2mg) achieved 9.6% weight reduction (21.2 lbs). 9mg achieved 7% (15.9 lbs), 5.5mg achieved 5.1% (11.7 lbs). Demonstrated efficacy extends to patients with comorbid diabetes and obesity.
All doses significantly reduced HbA1c by 1.3-1.6% from 8.0% baseline vs 0.4% placebo. 76.2% achieved HbA1c <7%, 66.0% achieved ≤6.5%. 36mg dose produced 7.9% weight reduction (16 lbs). First oral GLP-1 with no food/water restrictions to complete Phase 3.